Home/Solid Biosciences/Dr. Gabriel Brooks, M.D.
DG

Dr. Gabriel Brooks, M.D.

Chief Medical Officer

Solid Biosciences

Solid Biosciences Pipeline

DrugIndicationPhase
SGT-003Duchenne Muscular Dystrophy (Duchenne)Phase I/II
SGT-212Friedreich’s ataxia (FA)Phase I/II
SGT-501Catecholaminergic polymorphic ventricular tachycardia (CPVT)Phase I/II
SGT-601TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseasesPreclinical